If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEagle Eye Regulatory News (EYE)

Share Price Information for Eagle Eye (EYE)

Share Price is delayed by 15 minutes
Get Live Data
475.00    0.00 (0.00%)
Bid:
470.00
Ask:
480.00
Spread: 10.00 (2.128%)
Market Cap: £143.57m
EYE Live PriceLast checked at - London Stock Exchange

Intraday Eagle Eye Share Chart

PDMR shareholding & issue of equity - replacement

21 May 2026 14:47

RNS Number : 3340F
Eagle Eye Solutions Group PLC
21 May 2026
 

The following amendment has been made to the 'PDMR shareholding and issue of equity' announcement released on 21 May 2026 at 13:35 under RNS No 3279F.

 

The expected Admission date for the 10,000 new Ordinary Shares to be admitted to trading on AIM has been amended from '29 April 2026' to '28 May 2026'.

 

All other details remain unchanged.

 

The full amended text is shown below.

 

21 May 2026

Eagle Eye Solutions Group PLC

 

("Eagle Eye" or the "Company")

 

PDMR shareholding and issue of equity

 

Eagle Eye, a leading provider of applied AI for marketing, enabling personalised, real-time engagement at scale, announces that James Esson, Company Secretary, has exercised options over ordinary shares of 1 pence each ("Ordinary Shares") at a price of £2.685 per share and sold the resultant Ordinary Shares at a price of £4.12 per Ordinary Share as set out in the table below:

Senior Personnel

Role

Number of options in Ordinary Shares subject to exercise

Number of Ordinary Shares subject to sale

Total number of Ordinary Shares held post sale

% of existing issued share capital

James Esson

Company Secretary

10,000

10,000

-

0.0%

 

An application has been made for the 10,000 new Ordinary Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will occur on or around 28 May 2026.

Following the issue of the new Ordinary Shares, the total number of Ordinary Shares in issue is 30,222,736, with each share carrying the right to one vote. There are 330,976 shares held in Treasury. The total number of voting rights in the Company is, therefore, 29,891,760.

The above figure of 29,891,760 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the FCA's Disclosure and Transparency Rules.

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

 

 

Name

James Esson

2

Reason for the notification

a)

 

 

Position/status

Company Secretary

 

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Eagle Eye Solutions Group plc

b)

LEI

2138002S1AIBVVMZ7A21

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

 

Ordinary shares of 1p each

 

GB00BKF1YD83

b)

Nature of transaction

1a) Exercise of share options over Ordinary Shares

1b) Sale of Ordinary Shares

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

1a) £2.685 exercise price per share

1b) £4.12 sale price per share

 

1a) 10,000

1b) 10,000

 

Aggregated information

- Aggregated volume

- Price

N/A

 

e)

Date of the transaction

1a) 21 May 2026

1b) 21 May 2026

 

f)

Place of the transaction

1a) Outside of a trading venue

1b) AIM, London Stock Exchange

 

 

Enquiries:

Eagle Eye Solutions Group plc

Tel: 0844 824 3686

Tim Mason, Chief Executive Officer

 

Lucy Sharman-Munday, Chief Financial Officer

 

 

 

 

Canaccord Genuity Limited (Nominated Adviser and Joint Broker)

Tel: +44 20 7523 8000

Simon Bridges, Harry Gooden, Andrew Potts, Elizabeth Halley-Stott

 

 

Shore Capital (Joint Broker)

Tel: +44 20 7408 4090

Corporate Advisory: Daniel Bush, David Coaten, Lucy Bowden

 

Corporate Broking: Henry Willcocks

 

 

 

 

Alma Strategic Communications

Tel: +44 20 3405 0205

Caroline Forde, Hannah Campbell, Kinvara Verdon

 

 

About Eagle Eye

 

Eagle Eye is a leading provider of applied AI for marketing, enabling personalised, real-time engagement at scale for retail, travel and hospitality brands globally. Our powerful technology combines the world's most flexible and scalable loyalty and promotions capability with cutting edge, built-for-purpose AI to deliver 1:1 personalisation at scale for enterprise businesses, globally.

 

Our growing customer base includes Loblaws, Southeastern Grocers, Giant Eagle, Asda, Tesco, Morrisons, JD Sports, E.Leclerc, Carrefour, the Woolworths Group and many more. Each week, more than 1 billion personalised offers are seamlessly executed via our platform, and over 700 million loyalty member wallets are managed worldwide. 

 

AI-powered, API-based and cloud-native, Eagle Eye's enterprise-grade technology is fully certified by the MACH Alliance and has received recognition from leading industry bodies, including Gartner, Forrester, IDC and QKS. 

 

Web - www.eagleeye.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHPPUCCAUPQGWG
Date   Source Headline
17th Jun 20261:12 pmRNSIssue of Equity
28th May 20267:00 amRNSSale of shares from treasury
21st May 20262:47 pmRNSPDMR shareholding & issue of equity - replacement
21st May 20261:35 pmRNSPDMR shareholding and issue of equity
21st May 20267:00 amRNSCapital Markets Day
27th Apr 20267:00 amRNSNotice of Capital Markets Day
24th Apr 202612:30 pmRNSPDMR Shareholding
23rd Apr 20268:11 amRNSPDMR shareholding and issue of equity
31st Mar 20262:02 pmRNSPCA Shareholding
20th Mar 202610:36 amRNSDirector/PDMR Shareholding
17th Mar 202612:11 pmRNSIssue of Equity
17th Mar 20267:00 amRNSHalf Year Results
17th Mar 20267:00 amRNSHalf Year Results
6th Mar 20267:00 amRNSTransaction in Own Shares & Programme Completion
5th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20265:18 pmRNSNotification of major holdings
2nd Mar 20262:43 pmRNSHolding(s) in Company
2nd Mar 20267:00 amRNSTransaction in Own Shares
27th Feb 20267:00 amRNSTransaction in Own Shares
26th Feb 20267:00 amRNSTransaction in Own Shares
25th Feb 20267:00 amRNSTransaction in Own Shares
24th Feb 20267:00 amRNSTransaction in Own Shares
20th Feb 20267:00 amRNSTransaction in Own Shares
18th Feb 20267:00 amRNSTransaction in Own Shares
12th Feb 20263:32 pmRNSDirector/PDMR Shareholding
12th Feb 202610:59 amRNSDirector/PDMR Shareholding
12th Feb 20267:00 amRNSTransaction in Own Shares
11th Feb 20267:00 amRNSTransaction in Own Shares
10th Feb 20267:00 amRNSTransaction in Own Shares
9th Feb 20267:00 amRNSTransaction in Own Shares
6th Feb 20267:00 amRNSTransaction in Own Shares
5th Feb 20267:00 amRNSTransaction in Own Shares
4th Feb 20267:00 amRNSTransaction in Own Shares
3rd Feb 20267:00 amRNSTransaction in Own Shares
2nd Feb 20267:00 amRNSExtension of Share Buyback Long Stop Expiry Date
29th Jan 20267:00 amRNSTransaction in Own Shares
26th Jan 20267:00 amRNSAppointment of Nominated Adviser and Joint Broker
23rd Jan 20263:48 pmRNSDirector Declaration Update
20th Jan 20267:00 amRNSH1 FY26 Trading Update and Notice of Results
20th Jan 20267:00 amRNSTransaction in Own Shares
19th Jan 20267:00 amRNSTransaction in Own Shares
13th Jan 20267:00 amRNSMajor US multi-year contract win
12th Jan 20267:00 amRNSTransaction in Own Shares
8th Jan 20267:00 amRNSTransaction in Own Shares
31st Dec 20257:00 amRNSTransaction in Own Shares
31st Dec 20257:00 amRNSTransaction in Own Shares
29th Dec 20257:00 amRNSTransaction in Own Shares
29th Dec 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.